Search

Considering the prevalence of obesity, diabetes and cardiovascular diseases, significant interest has been focused on the gut microbiota-diabetes and cardiovascular system interaction, because the gut microbiota has been recognized as a modulator of human health. Dysbiosis, characterized by pathological changes in the gut microbiota, has been reported in cardimetabolic disorders, such as overweight and obesity, dyslipidaemia, atherosclerosis and hypertension. Furthermore, dysbiosis can disturb gut immunity, which increases the risk of acute cardiometabolic events. Therefore, the changes in the composition of the gut microbiota can affect host metabolism and immunity. The aim of this review is to look through the current knowledge over gut microbiata and expand the view on key roles of intestinal microflora during development of cardiometabolic diseases as T2DM, hypertension, dyslipidemia and atherosclerosis, also discuss the roles of microbiata regulating agents such as pre- and probiotics.